Literature DB >> 16682545

Nerve conduction abnormalities in patients with MELAS and the A3243G mutation.

Petra Kaufmann1, Juan M Pascual, Yaacov Anziska, Clifton L Gooch, Kristin Engelstad, Sarah Jhung, Salvatore DiMauro, Darryl C De Vivo.   

Abstract

BACKGROUND: Mitochondrial DNA point mutations are especially deleterious to tissues with high energy demand, including the peripheral nervous system. Neuropathy has been associated with several mitochondrial diseases, including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes).
OBJECTIVE: To evaluate nerve conduction in a genotypically and phenotypically homogeneous group of patients with MELAS and the A3243G mutation.
DESIGN: We studied 30 patients with MELAS and the A3243G mutation using neurophysiological techniques, medical history questionnaires, laboratory tests, and a standardized neurological examination.
RESULTS: Twenty-three subjects (77%) had abnormal nerve conduction measures. Symptoms suggestive of neuropathy were present in only half of the patients, but almost all had decreased reflexes or distal sensory findings on examination. Nerve conduction abnormalities were predominantly axonal and sensory and mainly present in the legs. Patients with nerve conduction abnormalities tended to be older and were more likely male.
CONCLUSIONS: Peripheral nerve impairment is common in those with MELAS and the A3243G mutation, and may be subclinical. Male sex and older age may add to the genetic disposition to develop neuropathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682545     DOI: 10.1001/archneur.63.5.746

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  21 in total

Review 1.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2011-10-07       Impact factor: 4.797

Review 2.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

3.  The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients.

Authors:  Kavi P Patel; Thomas W O'Brien; Sankarasubramon H Subramony; Jonathan Shuster; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2012-07       Impact factor: 4.797

Review 4.  The neuro-ophthalmology of mitochondrial disease.

Authors:  J Alexander Fraser; Valérie Biousse; Nancy J Newman
Journal:  Surv Ophthalmol       Date:  2010-05-14       Impact factor: 6.048

Review 5.  Peripheral neuropathy and inborn errors of metabolism in adults.

Authors:  F Sedel; C Barnerias; O Dubourg; I Desguerres; O Lyon-Caen; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2007-09-21       Impact factor: 4.982

6.  Long-term safety of dichloroacetate in congenital lactic acidosis.

Authors:  Monica Abdelmalak; Alicia Lew; Ryan Ramezani; Albert L Shroads; Bonnie S Coats; Taimour Langaee; Meena N Shankar; Richard E Neiberger; S H Subramony; Peter W Stacpoole
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

7.  Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate.

Authors:  Peter W Stacpoole; Lesa R Gilbert; Richard E Neiberger; Paul R Carney; Edward Valenstein; Douglas W Theriaque; Jonathan J Shuster
Journal:  Pediatrics       Date:  2008-04-14       Impact factor: 7.124

Review 8.  Pharmacogenetic considerations with dichloroacetate dosing.

Authors:  Margaret O James; Peter W Stacpoole
Journal:  Pharmacogenomics       Date:  2016-05-04       Impact factor: 2.533

Review 9.  Review of clinical trials for mitochondrial disorders: 1997-2012.

Authors:  Douglas S Kerr
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

10.  Small-fiber neuropathy and the 3243A>G mutation in mitochondrial DNA.

Authors:  F Henning; P L Oey; W G Oerlemans; J H J Wokke
Journal:  J Neurol       Date:  2007-04-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.